Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.70 -0.41 (-2.75%)
Streaming Delayed Price Updated: 12:34 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products ↗
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing... 
Via Talk Markets
News headline image
The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene ↗
Auditing issues persist for some 270 companies trading in the U.S. But they could ease. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
News headline image
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗
 
Via Benzinga
News headline image
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
News headline image
Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. ↗
Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. 
Via InvestorPlace
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗
Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. 
Via InvestorPlace
News headline image
What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗
Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM... 
Via Benzinga
News headline image
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat ↗
Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
Via Benzinga
News headline image
Chinese Stocks Are Falling: What's Going On? ↗
Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as... 
Via Benzinga
News headline image
Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗
The SEC is calling out a several stocks for non-compliance. Could they face delisting? 
Via Investor's Business Daily
News headline image
Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition ↗
Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
Week In Review: Biopharma Deals Slow During Chinese New Year Week ↗
Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine... 
Via Talk Markets
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
News headline image
31 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
News headline image
18 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
Via Benzinga
News headline image
20 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per... 
Via Benzinga
News headline image
Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices ↗
Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of... 
Via Talk Markets
Topics Initial Public Offering
News headline image
HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China ↗
The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited... 
Via Benzinga
News headline image
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
News headline image
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China ↗
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (... 
Via Benzinga
News headline image
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
From Epizyme, Inc.
Via Business Wire
News headline image
62 Biggest Movers From Yesterday ↗
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.